# A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease

Study · id `cardio:ct-nct01503736` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01503736](<https://clinicaltrials.gov/study/NCT01503736>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01503736

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.

## Technical summary

Registry record NCT01503736. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 183 participants (enrolled count; ClinicalTrials.gov record NCT01503736, source copy `cardio:ctgov-nct01503736-2020-01-13`, retrieved 2026-10-26)
- Start date: 2010-06 (registry gives no type) (ClinicalTrials.gov record NCT01503736, source copy `cardio:ctgov-nct01503736-2020-01-13`, retrieved 2026-10-26)
- Primary completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01503736, source copy `cardio:ctgov-nct01503736-2020-01-13`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: Taiwan (ClinicalTrials.gov record NCT01503736, source copy `cardio:ctgov-nct01503736-2020-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01503736-2020-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
- Condition: Hyperphosphatemia
- Condition: End Stage Renal Disease
- Condition: ESRD
- Intervention (Drug): ferric citrate
- Intervention (Drug): ferric citrate
- Intervention (Drug): ferric citrate
- Lead sponsor: Panion & BF Biotech Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Panion & BF Biotech Inc. (`cardio:org-panion-bf-biotech-inc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study (`cardio:pubmed-24840781`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c09849ffe3bc584954237ede2177628ab0104c5578a5b7c6e8d5526efa8c8412
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
